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FDA Restrictions on Mifepristone: Time for a Change? 
Abstract 
Mifepristone, a drug used to manage early miscarriage or end an early pregnancy, carries unique 
restrictions imposed by the U.S. Food and Drug Administration (FDA). Patients are required to pick up the 
drug in person from a doctor or a clinic, even though they can take the drug at home. In July, a federal 
court ruled that the FDA must suspend these restrictions during the COVID-19 pandemic, for patients 
seeking an early abortion, although the ruling did not apply to women with an early pregnancy loss. But 
the challenges to FDA restrictions on mifepristone predate the pandemic. This Issue Brief provides the 
context for this ongoing controversy, and reviews recent evidence on the clinical and cost effectiveness of 
mifepristone for the medical management of first trimester miscarriage. 
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INTRODUCTION 
The FDA approved mifepristone (also known as RU486) in 2000 
with safety restrictions that involve a Risk Evaluation and Mitigation 
Strategy (REMS). Under REMS, mifepristone must be dispensed 
through registered clinicians only, and patients must sign an FDA-
approved agreement before receiving the medication. By most 
accounts, these restrictions stem from the use of mifepristone, in 
combination with another medication, misoprostol, for medically-
induced early abortion. As a result, mifepristone is not available 
through retail or mail-order pharmacies, and most physicians do not 
stock the drug. 
In the 20 years since then, medical professional organizations and 
advocacy groups have challenged these restrictions in court, citing 
evidence of drug’s safety and efficacy. In July 2020, a federal district 
court held that the FDA could not enforce these restrictions on 
women seeking a medical abortion during a pandemic, because of the 
risk posed by requiring in-person visits to pick up the medication. The 
ruling raises longer-term questions about whether the FDA should 
reconsider the REMS restrictions entirely, especially in light of recent 
evidence on the clinical and cost effectiveness of mifepristone in the 
medical management of early miscarriage. 
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FDA RESTRICTIONS ON MIFEPRISTONE: 
TIME FOR A CHANGE? 
Recent studies confirm clinical and cost effectiveness for 
medical management of early miscarriage
Janet Weiner, PhD, MPH and Courtney A. Schreiber, MD, MPH
Mifepristone, a drug used to manage early miscarriage or end an early pregnancy, carries unique restrictions 
imposed by the U.S. Food and Drug Administration (FDA). Patients are required to pick up the drug in person 
from a doctor or a clinic, even though they can take the drug at home. In July, a federal court ruled that the 
FDA must suspend these restrictions during the COVID-19 pandemic, for patients seeking an early abortion, 
although the ruling did not apply to women with an early pregnancy loss. But the challenges to FDA restrictions 
on mifepristone predate the pandemic. This Issue Brief provides the context for this ongoing controversy, and 
reviews recent evidence on the clinical and cost effectiveness of mifepristone for the medical management of 
first trimester miscarriage.
MIFEPRISTONE PRETREATMENT  
AND PREGNANCY LOSS
Each year, more than one million women in the United States 
miscarry in the first trimester. Often, ultrasound reveals a nonviable 
pregnancy, and women face the difficult and painful choice of waiting 
for a miscarriage to progress, or surgical or medical interventions 
to help complete the miscarriage process. Many women prefer 
medical management (medications that they can take at home to 
induce uterine contractions) rather than surgery (uterine aspiration). 
The most commonly used medical therapy is misoprostol (self-
administered), which fails about 30% of the time, leading to prolonged 
treatment or eventual surgical management. Another option is to give 
women mifepristone first (orally) followed by misoprostol, 24 hours 
later. However, the FDA restrictions on mifepristone have limited 
access to the drug and, until recently, the efficacy of pretreating with 
mifepristone was unclear in these circumstances.
RANDOMIZED TRIAL SHOWS MIFEPRISTONE 
PRETREATMENT IS 25% MORE EFFECTIVE 
THAN MISOPROSTOL ALONE 
Courtney Schreiber and colleagues conducted a randomized trial 
of mifepristone pretreatment in 300 women with early pregnancy 
loss, and assessed its efficacy and safety compared to misoprostol 
only. The landmark study, published in the New England Journal of 
Medicine, found that pretreatment with mifepristone was more 25% 
more effective than misoprostol alone in successful management of 
early pregnancy loss.1 The combination of drugs led to completion 
of the miscarriage after one course of treatment in 83.8% of 
women, compared to 67.1% of women receiving misoprostol alone. 
Fewer women in the pretreatment group needed eventual surgical 
intervention (8.8% vs. 23.5%). In terms of safety, the study found 
no significant difference between the groups in adverse events 
(infections or blood transfusions).
The study provided compelling evidence that pretreatment with 
mifepristone is safe and effective for women with early pregnancy 
loss. After the study was released in 2018, the American College of 
Obstetrics and Gynecology called for the removal of “outdated” 
REMS requirements for mifepristone, saying that the restrictions 
substantially limit access to a safe, effective medication. 
MIFEPRISTONE PRETREATMENT  
IS COST EFFECTIVE
Another consideration in the use of mifepristone pretreatment is 
whether it is cost effective, at roughly $90 a pill (misoprostol alone 
can cost less than one dollar). Schreiber and colleagues conducted an 
economic evaluation alongside the clinical trial to estimate the cost-
effectiveness of adding mifepristone to the medical management of 
miscarriage. In a study published in earlier this year in JAMA Network 
Open, they found that mifepristone pretreatment represents good 
value from both the perspective of the health sector and society.2 
They analyzed direct health care costs in the 30 days after enrollment 
in the trial, as well as more indirect societal costs such as patients’ time 
and lost wages. They found that average health care costs were the 
same in the two groups: in 2018 dollars, $697 for women receiving 
mifepristone and misoprostol versus $691 for women receiving 
misoprostol alone. From the societal perspective, average costs per 
patient were $3,846 for mifepristone and misoprostol and $4,846 for 
misoprostol alone — a $1,000 difference. 
REMS AND THE REGULATION 
OF MIFEPRISTONE
Currently, the FDA has 59 REMS programs in place, 86% of which 
include “elements to assure safe use” such as clinician registration 
or special training. The programs are usually applied to drugs with 
serious complications or contraindications, such as antipsychotics, 
opioids, testosterone, and several drugs used to treat cancer, acne, 
and multiple sclerosis.
In response to 15 years of safety information, in 2016 the FDA 
revised its initial REMS requirements for mifepristone. The changes 
included expansion of the gestational limit for treatment from 49 to 
70 days, omission of the recommendation for in-person follow-up, and 
removal of a requirement that the prescriber be a physician. However, 
the requirement that the drug be dispensed by a certified provider 
remained intact. 
In 2017, the American Civil Liberties Union (ACLU) filed a lawsuit, on 
behalf of a group of providers, challenging the REMS requirements 
for mifepristone. They cited low rates of complications associated with 
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In 2018, the American College of 
Obstetrics and Gynecology called 
for the removal of “outdated” REMS 
requirements for mifepristone, saying 
that the restrictions substantially limit 
access to a safe, effective medication.  
medical abortions and pointed to other drugs with more serious risks that did not carry REMS 
restrictions. The suit maintains that the REMS restrictions needlessly complicate access to the 
drug, particularly in rural or medically underserved areas. That case is still pending. 
In 2019, a former FDA Commissioner published a perspective in the New England Journal of 
Medicine arguing the distribution restrictions imposed by the FDA were no longer appropriate 
given nearly two decades of use and evidence that mifepristone is extremely safe and effective.
And in response to the COVID-19 pandemic, the ACLU filed another lawsuit challenging the 
REMS requirement that mifepristone be dispensed in person. The court issued a nationwide 
preliminary injunction blocking part of the FDA’s REMS restrictions on mifepristone when it is 
used for medication abortion, yet failed to suspend the restrictions when the medication is used 
for managing an early miscarriage. The temporary easing of the in-person requirements allows 
mifepristone to be mailed from health facilities to the patient where state law permits. The 
injunction will last for the duration of the litigation, or until the administration ends the federal 
public health emergency declaration.
POLICY IMPLICATIONS
The latest evidence of mifepristone’s clinical and cost effectiveness adds an important 
perspective to the controversy surrounding its regulation and availability. REMS regulations 
were promulgated when existing safety data were scarce amid debates about medical abortion. 
But for women with early pregnancy loss, experts believe that restrictive regulations reduce 
access to now-recommended medical regimens to manage the process of miscarriage. The 
evidence on the clinical and cost effectiveness of mifepristone pretreatment is clear, and 
warrants a new look by FDA regulators. And in the midst of a pandemic, requiring in-person 
dispensing is a risk no woman with an early pregnancy loss should have to face.
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